- Home
- STTK vs BGSF Comparison
STTK vs BGSF Comparison
Compare STTK & BGSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- BGSF
- Stock Information
- Founded
- STTK 2016
- BGSF 2007
- Country
- STTK United States
- BGSF United States
- Employees
- STTK N/A
- BGSF N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- BGSF Professional Services
- Sector
- STTK Health Care
- BGSF Consumer Discretionary
- Exchange
- STTK Nasdaq
- BGSF Nasdaq
- Market Cap
- STTK 56.8M
- BGSF 66.0M
- IPO Year
- STTK 2020
- BGSF N/A
- Fundamental
- Price
- STTK $1.11
- BGSF $5.23
- Analyst Decision
- STTK Hold
- BGSF
- Analyst Count
- STTK 3
- BGSF 0
- Target Price
- STTK $2.00
- BGSF N/A
- AVG Volume (30 Days)
- STTK 172.1K
- BGSF 24.8K
- Earning Date
- STTK 02-27-2025
- BGSF 03-12-2025
- Dividend Yield
- STTK N/A
- BGSF 2.85%
- EPS Growth
- STTK N/A
- BGSF N/A
- EPS
- STTK N/A
- BGSF N/A
- Revenue
- STTK $6,435,000.00
- BGSF $281,656,000.00
- Revenue This Year
- STTK $313.04
- BGSF N/A
- Revenue Next Year
- STTK N/A
- BGSF $5.63
- P/E Ratio
- STTK N/A
- BGSF N/A
- Revenue Growth
- STTK 382.75
- BGSF N/A
- 52 Week Low
- STTK $0.94
- BGSF $5.14
- 52 Week High
- STTK $11.76
- BGSF $10.74
- Technical
- Relative Strength Index (RSI)
- STTK 44.36
- BGSF 38.53
- Support Level
- STTK $1.13
- BGSF $5.20
- Resistance Level
- STTK $1.22
- BGSF $5.55
- Average True Range (ATR)
- STTK 0.11
- BGSF 0.31
- MACD
- STTK -0.01
- BGSF -0.02
- Stochastic Oscillator
- STTK 15.15
- BGSF 8.65
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About BGSF BGSF Inc.
BGSF Inc is a provider of workforce solutions operating primarily in the U.S. across two segments: Property Management and Professional. In the Property Management segment, BGSF offers office and maintenance talent to clients, facilitating their staffing needs with short-term and consulting solutions. The Professional segment specializes in IT, offering skilled professionals in SAP, Workday, and other areas to Fortune 500 companies and consulting firms nationwide. BGSF's workforce services include on-demand assignments, consulting, and managed solutions, allowing clients to flexibly manage their workforce needs. With a focus on converting fixed personnel costs to variable expenses, BGSF enables companies to effectively address fluctuations in demand while optimizing costs.